GlassScriptPhysician profile
Caitlin Grant Collier
NPI 1376209163
$4,168.26
in general payments reported to CMS, 2019-2025
21 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $365 · 2023: $1,191 · 2024: $1,490 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722 · Education: $80.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,722.46 |
| Education | $80.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,310.26 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $878.57 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $494.67 | 2022-2025 | Xifaxan |
| Janssen Biotech, INC. | $290.77 | 2022-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $290.23 | 2023-2025 | |
| Celltrion USA INC. | $177.96 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $137.99 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $91.87 | 2023-2024 | Voquezna |
| Madrigal Pharmaceuticals | $86.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $75.84 | 2024 | Omvoh |
| Evoke Pharma, INC. | $58.65 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $56.28 | 2024 | Dupixent |
| Intra-Sana Laboratories | $50.00 | 2023 | Reltone 400 Mg, Reltone 200 Mg |
| Ironwood Pharmaceuticals, INC | $34.69 | 2023 | Linzess |
| Aimmune Therapeutics, INC. | $23.37 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.83 | 2022 | |
| Amgen INC. | $19.68 | 2023 | Amjevita, Avsola |
| Intercept Pharmaceuticals, INC. | $19.60 | 2023 | Ocaliva |
| Braintree Laboratories, INC. | $18.10 | 2023 | Suflave |
| Organon LLC | $16.80 | 2023 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.